HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma. Koskela H, Li Y, Joutsiniemi T, Muranen T, et al. Gynecol Oncol 2023;180:91-98.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Koskela H, Li Y, Joutsiniemi T, Muranen T, et al. HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma. Gynecol Oncol 2023;180:91-98.
PMID: 38061276